NewsBenzinga周日报道，Cue生物制药的CUE-221在2期慢性自发性荨麻疹研究中，4mg/kg剂量停药12周后显示出60%的完全荨麻疹缓解，而奥马利珠单抗则为24%。 周日报道，Cue生物制药的CUE-221在2期慢性自发性荨麻疹研究中，4mg/kg剂量停药12周后显示出60%的完全荨麻疹缓解，而奥马利珠单抗则为24%。 Benzinga 2026.09.21 06:32 (GMT+0) Open on Benzinga Other news Barclays Maintains Equal-Weight on Exelon, Lowers Price Target to $44 The FTC Allows Publicis’ LiveRamp Acquisition To Move Forward With Safeguards To Protect Customer Data And Fair Competition. Citizens Financial Analysts Slash Their Forecasts Following Q3 Results Barclays Maintains Overweight on Evergy, Lowers Price Target to $86 Mastercard Brings Its Fraud-Fighting Tools to Stablecoin Payments Barclays Maintains Overweight on Entergy, Lowers Price Target to $115
The FTC Allows Publicis’ LiveRamp Acquisition To Move Forward With Safeguards To Protect Customer Data And Fair Competition.
